We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
-4.13%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$706M
AUM Growth
-$264M
(-27%)
Cap. Flow
-$179M
Cap. Flow
% of AUM
-25.29%
Top 10 Holdings %
Top 10 Hldgs %
84.23%
Holding
36
New
6
Increased
4
Reduced
10
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$34.5M |
| 2 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
+$18.4M |
| 3 |
MYOV
Myovant Sciences Ltd.
MYOV
|
+$17.4M |
| 4 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$8.51M |
| 5 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$8.47M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
|
+$70M |
| 2 |
Nektar Therapeutics
NKTR
|
+$63M |
| 3 |
Aclaris Therapeutics
ACRS
|
+$39.6M |
| 4 |
TG Therapeutics
TGTX
|
+$21.3M |
| 5 |
Ardelyx
ARDX
|
+$18.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AKTX
26
Akari Therapeutics
AKTX
$14.4M
| $714K | 0.1% |
127
-16
| -11% | -$103K |
|
|
ORKA
27
Oruka Therapeutics
ORKA
$5.31B
| $662K | 0.09% |
1,075
-1,340
| -55% | -$713K |
|
|
28
Aclaris Therapeutics
ACRS
$715M
| – | – |
-1,547,152
| Closed | -$39.6M |
|
29
Arcturus Therapeutics
ARCT
$165M
| – | – |
-292,108
| Closed | -$5.05M |
|
30
Arrowhead Research
ARWR
$12.1B
| – | – |
-1,525,424
| Closed | -$11.2M |
|
|
31
Nektar Therapeutics
NKTR
$2.39B
| – | – |
-244,277
| Closed | -$63M |
|
|
SGMO
32
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| – | – |
-899,438
| Closed | -$4.16M |
|
33
Spyre Therapeutics
SYRE
$8.5B
| – | – |
-13,445
| Closed | -$2.15M |
|
34
Protara Therapeutics
TARA
$214M
| – | – |
-40,673
| Closed | -$15.2M |
|
|
SIOX
35
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| – | – |
-625,000
| Closed | -$70M |
|
|
XLRN
36
DELISTED
Acceleron Pharma
XLRN
| – | – |
-318,565
| Closed | -$11.5M |
|
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q4 2016 Portfolio in Review
As of Q4 2016, RA Capital Management held 36 positions worth $706M, down 27% from $969M the previous quarter. Its ten largest holdings account for 84% of the portfolio.
RA Capital Management withdrew a net $179M in Q4 2016, closing 9 positions and reducing 10 holdings. Its most notable exit was Sio Gene Therapies Inc. Common Stock, an estimated $70M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier.
Against the trend, RA Capital Management opened a new position in Ra Pharmaceuticals, Inc. Common Stock worth $20.5M.
- RA Capital Management's largest Q4 2016 buy was Ra Pharmaceuticals, Inc. Common Stock: 1,351,808 shares worth $20.5M.
- RA Capital Management added most to Ascendis Pharma A/S in Q4 2016, an estimated $34.5M increase.
- RA Capital Management's biggest Q4 2016 reduction was TG Therapeutics, cutting an estimated $21.3M.
- RA Capital Management fully exited Sio Gene Therapies Inc. Common Stock in Q4 2016, selling an estimated $70M.
- RA Capital Management's ten largest holdings make up 84% of its $706M portfolio in Q4 2016.
- RA Capital Management opened 6 new positions and closed 9 in Q4 2016.
- RA Capital Management's portfolio value fell 27% quarter-over-quarter to $706M.
Based on RA Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.